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This study aimed to investigate the pharmacokinetics of a hematoporphyrin derivative in colonic tumors induced by dimethylhy-
drazine and adjacent normal colon in Wistar rats using an in vivo fluorescence spectroscopy technique. In conventional clinical
application of photodynamic therapy, the interval between photosensitizer (PS) administration and lesion illumination is often
standardized without taking into account variations due to the type or localization of the tumor and intrinsic diﬀerences in the
microcirculation and vascular permeability of each target organ. The analysis of the fluorescence spectra was based on the intensity
of porphyrin emission band centered at around 620 nm in normal colon and colon tumors. The photosensitizer fluorescence
intensity rapidly grew for carcinoma and normal colon, reaching themaximum values 1 and 3 hours after PS injection, respectively.
Data presented here allow us to verify that the best compromise between selectivity and drug concentration for colon carcinoma
in rats took place in the interval between 1 to 4 h after PS injection.
1. Introduction
Photodynamic therapy (PDT) is an established modality
for the treatment against some types of cancers and other
nononcologic diseases. PDT involves the interaction of the
photosensitizer with a visible light of a specific wavelength
and oxygen. The therapeutic eﬀect occurs during the
absorption of light, energy by the photosensitizer leading
to excited state, generating highly reactive oxygen species,
which destroys cellular substrates and leads to cell death. The
eﬀects of PDT depend on the simultaneous presence of the
PS, excitation light and oxygen [1, 2]. Although oxidative
damage is one important component contributing to tumor
therapy outcome with PDT, the eﬀects on tumor vasculature
interlinked with elicited host response also play a critical role
[3].
The eﬃciency of PDT is directly related to several factors
inherent to the target tissue (cellular and vascular structure
of the tumor), photosensitizer (selectivity, solubility in lipid,
and cellular placement), and parameters of irradiation, such
as wavelength (nm), energy doses (J/cm2), and intensity
(W/cm2) [4].
Selectivity of treatment is imparted by a combination
of factors, including accumulation of photosensitizer (PS)
by the target lesion and the time interval between the
PS administration and lesion illumination [5–7]. In con-
ventional clinical application of PDT, the interval between
photosensitizer administration and lesion illumination is
often standardized, without taking into account variations
due to the type or localization of the tumor. In this form,
tumors in the skin, liver, kidneys, intestine, and other
organs are considered similar concerning PS accumulation
or even its selectivity. Beside the intrinsic diﬀerences of each
organ, there are still diﬀerences own to each type of tumor,
associated to structural diﬀerences in the microcirculation
and vascular permeability. The standardization of interval
2 International Journal of Photoenergy
between photosensitizer application and illumination for all
tumor types is not appropriated due to the physiological
dependence of the vascularization, mainly when a systemic
administration of PS is considered [6].
Most of the experimental studies use the same interval
between the administration of the FS and the lesion illumi-
nation taking into account only the PS used. Perhaps this
is one of the reasons why diﬀerent results are presented
in the literature. In order to improve PDT, the study of
temporal evolution of photosensitizer distribution should be
done before planning PDT experiments involving treatment
of tumor lesions [6].
Fluorescence spectroscopy has been performed exten-
sively in animal models to evaluate the uptake of photosensi-
tizing agents for photodynamic therapy [6, 8]. The method
of in vivo fluorescence spectroscopy is a rapid and useful
technique that may be readily applied to obtain information
related to the pharmacokinetic behavior of fluorescent drugs
[9, 10]. Although the absolute concentration of sensitizer is
diﬃcult to be established, fluorescent monitoring is suitable
to follow the time variation for the accumulation of a specific
PS after injection using the fluorescence peaks associated
with this photosensitizer in several tissues [6]. One of the
advantages of this technique over other types of fluorescence
methods, such as fluorescence microscopy [5, 11, 12] and
radiolabeling technique [13, 14], is the fact that the sacrifice
of the animals for the measurements is not necessary, thus
reducing the number of animals sacrificed to obtain a given
amount of information [6, 15]. It also allows simultaneous
multiple measurements of a site with optic fiber bundle
delivery system and a charge-coupled device. Furthermore,
it permits easy access to internal hollow organs by endoscopy
[15].
In this study PS uptake measurements were carried
out to evaluate the maximal tissue accumulation of the
PS (Photogem) in dimethylhydrazine- (DMH-) induced
colonic tumors and adjacent normal colon in Wistar rats
using an in vivo fluorescence spectroscopy technique. This
study shall provide information that can be used in future
PDT investigations in this experimental animal colon tumor
model.
2. Materials andMethods
2.1. Animals. The whole experiment was carried out in
accordance with the guidelines of the Committee of Ethics
in Research of Universidade Federal de Sa˜o Paulo for
animal care (Protocol number: 1033/05). The male Wistar
rats, 180 g weight, received subcutaneous injections of 1,2-
dimethylhydrazine (DMH-Aldrich Chemical Co., Milwau-
kee, WI, USA) on the dose of 65mg/kg at weekly interval
for five weeks for tumor induction. The animals were kept
under adequate conditions and observed for 16 to 18 weeks,
the time required for the development of intestinal tumors
[16].
2.2. Photosensitizer. The PS chosen for this study is Pho-
togem. This is a hematoporphyrin derivative, made by
Photogem LLC Co. (Moscow, Russia). It is usually described
as chemically similar to Photofrin. Both Photogem and
Photofrin are mixtures of monomers, dimers, and oligomers
of hematoporphyrin derivatives and first-generation PSs.
The 5mg/mL stock solutions of Photogem in 20mM
phosphate-buﬀered saline, pH 7.4, were stored in the dark
at 4◦C [17–22].
2.3. Fluorescence System. Fluorescence collection was ob-
tained using a commercial system (Spectral-Fluorescence
System for Diagnosis of Malignant Tumors, “Spectr-Cluster,”
v. 2.05m, Cluster Ltd., Moscow, Russia) composed of a Y-
type optical fiber which delivers the laser light through a
central fiber and collects the fluorescence from a target tissue
using six fibers distributed around central one (integrant
part of the system, by Cluster Ltd., Moscow, Russia) and
a spectrometer (also built into the commercial system, by
Cluster Ltd., Moscow, Russia) to collect fluorescence in the
visible to near infrared range (540–850 nm).
The excitation light source was the 532 nm line of
Nd:YAG laser with 10mW of power, which is low enough to
avoid thermal eﬀects in the target tissue. This wavelength was
chosen for fluorescence spectroscopy since it represents good
cost-benefit commitment between light penetration in tissue
and fluorescence excitation of porphyrins (although longer
wavelengths would allow deeper evaluation, PS excitation
would not be observed for those regions). The fluorescent
light was filtered with standard optical filter placed at
the spectrometer entrance, avoiding the influence of the
fluorescence excitation. Figure 1 shows a schematic of the
design, illustrating the components of the system.
2.4. Fluorescence Measurements. The animal was anes-
thetized with xylazine (5mg/kg), ketamine (75mg/kg), and
butorphanol (1mg/kg) injected intraperitoneal (i.p.). A
midline laparotomy was performed, the site of the tumor
was identified by palpation, and a longitudinal colostomy
was carried out to 2 cm of distance of the opposite the
tumor base. Photogemwas administered at a dose of 2mg/kg
intravenously on the left caudal vein. The optical fiber was
perpendicularly positioned on the surface, touching the
tissue (Figure 2), in which fluorescence was evaluated at
regular time intervals. For all the kinetics measurements,
time t = 0 corresponds to the end of the injection. After the
spectral acquisition of each point, the optical fiber tip was
cleaned with physiological solution of 0.9% sodium chloride.
Animals presented 4 colon tumors (2 tumors/animal), for
each one, and fluorescence spectra were collected at three
diﬀerent positions. Each data point is the average of three
individual measurements in close regions of the lesion or
the normal tissue investigated. Such averaging is relevant to
avoid eventual laser intensity fluctuations. The fluorescence
from 540 to 800 nm was recorded in real time, and the
specific emission bands were used to quantify the amount
of PS present in the observed tissue. All the spectra were
normalized using the maximum amplitude at the excitation
wavelength, observed as a peak in the fluorescence graphs.
Data collection and treatment for normal tissue fluorescence
was performed likewise.
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Figure 1: Schematic representation for the experimental setup.
Figure 2: Fluorescence spectra acquisition in dimethylhydrazine-
induced murine colorectal carcinoma.
2.5. Histological Analysis. After fluorescence measurements,
samples of the normal colon and colon carcinoma were
collected and placed in 10% neutral buﬀered formalin for
routine histology preparation and hematoxylin and eosin
(H&E) staining for histological examination.
3. Results
Results in Figure 3 show typical autofluorescence (i.e., from
nonsensitized tissue) spectra from colon carcinoma and
normal colon. Two fluorescence peaks are observable, one at
around 620 nm and another at around 680 nm, mainly in the
colon carcinoma spectrum.
Figure 4 shows a temporal sequence of plots with colon
carcinoma and normal colon spectrum obtained in diﬀerent
times after the PS administration. The presented spectra were
normalized to the peak observed at excitation wavelength
(as described), and the tissue autofluorescence previous
to injection (as shown in Figure 3) was subtracted from
the collected fluorescence signal during pharmacokinetics.
Knowledge of the autofluorescence spectrum before injec-
tion allowed for subtraction of this component to obtain the
fluorescence spectrum of PS at several time intervals after
injection [15]. Table 1 shows the relative concentration of
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Figure 3: Typical fluorescence emission spectra from colon carci-
noma and normal colon.
Table 1: The relative concentration of Photogem in colon car-
cinoma and normal colon according to fluorescence intensity at
622 nm as a function of time after PS administration is presented.
Data is shown as the respective values and standard deviation (SD).
Fluorescence signal ± SD
Time (h) Colon carcinoma Normal colon
1 51.76± 7.65 28.29± 9.12
2 46.42± 11.51 34.36± 3.55
3 45.53± 5.11 36.46± 14.40
4 45.62± 3.24 33.70± 7.58
5 33.74± 4.91 29.59± 5.22
6 28.07± 7.84 27.95± 13.46
7 25.61± 5.16 25.92± 4.35
8 24.97± 7.49 23.77± 5.42
Photogem in colon carcinoma and normal colon according
to fluorescence intensity at 622 nm as a function of time after
PS administration.
In order to determine the time for accumulation in
minutes (Tacc(min)) and for elimination (Telim) of the pho-
tosensitizer, a simple exponential law for each regime was
considered. Origin (version 8.0) software was used to fit
experimental data. Fitting was performed using the equation
C = C0
(
1− e−t/Tacc
)
(1)
for accumulation and
C = C0e−t/Telim (2)
for elimination ((1) and (2)) in which C represents the
concentration-related fluorescence signal, C0 represents the
initial concentration-related fluorescence signal, t represents
time, and τ represents the accumulation (Tacc) or elimination
(Telim) rates. Tacc and Telim were both obtained by the best
fit of equations (Table 2). First of all we observe a selectivity
eﬀects; colon carcinoma has always an uptake higher than
normal tissue, based in the best fitting (Figure 5).
In this study, selectivity is assumed to be defined as the PS
fluorescence intensity of the colon carcinoma (FIcarc) plus the
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Figure 4: Temporal sequence of colon carcinoma and normal colon fluorescence spectra after intravenous injection of Photogem ((a) = 1 h;
(b) = 2 h; (c) = 3 h; (d) = 4 h; (e) = 5 h; (f) = 6 h).
PS fluorescence intensity of normal colon (FInormal), divided
by FInormal:
S = (FIcarc + FInormal)
FInormal
. (3)
This parameter represents the ability to diﬀerentiate tu-
mor tissue from normal tissue using fluorescence spectrosco-
py information. Selectivity values are shown in Table 3 and
Figure 6.
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Figure 5: Fitting of the accumulative evolution as well as the
elimination time evolution with the equations presented in the text.
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Figure 6: Fitting of the selectivity ratio between tumor and normal
tissue.
Table 2: Time for accumulation (Tacc) and elimination (Telim) of
the photosensitizer obtained for the normal and colon carcinoma,
presented both in minutes.
Tacc(min) Telim
Normal colon 40min 720min
Colon carcinoma 47min 540min
4. Discussion
Fluorescence intensity of photosensitizer as a function of
time after intravenous injection is reported for an experi-
mental animal colon tumor model using in vivo fluorescence
spectroscopy technique.
Fluorescence collection was used in this study as an
evaluator of the PS concentration in tissue, since it has been
observed in the literature that there is a correlation between
PS fluorescence and concentration [19]. Presently, one is
Table 3: Selectivity values as a function of time.
Time (h) Selectivity
1 2.48
2 0.80
3 0.54
4 0.83
5 0.43
6 0.08
7 0.05
8 0.35
not able to obtain the exact amount of PS concentration
from fluorescence spectroscopy measurements. Hence, it
is assumed that the normalized fluorescence spectra can
give one information about the actual PS concentration
in vivo. Therefore, in this study, the information related
to concentration is completely based on the fluorescence
collection.
This study does not take into account variations on flu-
orescence collection due to tumor dynamics and/or growth
rate, because the technique here used is not able to take those
variations into account properly (it is not the main issue of
the study, anyway, since it aims to an evaluation that can be
easily performed in preclinical and clinical trials).
The fluorescence peaks observed in Figure 3 (which was
collected before the PS administration) can be attributed to
the presence of endogenous porphyrins, possibly related to
either an altered metabolism of the cancer tissue or microbial
synthesis [8, 23]. After photosensitizer injection the appear-
ance of the emission bands associated with the presence of
porphyrin is evident in all spectra, especially in the band
centered around 620 nm, one of main fluorescence band of
the Photogem [6, 24]. Therefore, the accumulation of Pho-
togem was evaluated by the diﬀerence at the main peak at
622 nm. The amplitude of these emission peaks can be
associated with relative porphyrin quantities present in the
tissue, which are related to the fluorescence spectrum of the
photosensitizer previous to injection. It cannot be, however,
associated with absolute concentration, due to fluorescence
distortions observed for porphyrins in tissue, which make
diﬃcult to extract information that can be associated with
accurate concentration values [6].
Considering the additional amplitude of photosensitized
tissue fluorescence as being proportional to the tissue
concentration of photosensitizer, we observe that for tumor
tissue the time of maximum accumulation is around 1 h and
for the normal tissue 3 h (Table 1). Since the time variation of
the photosensitizer fluorescence is the compromise between
accumulation and clearance, we will consider that, initially,
this compromise is dominated by the accumulation of
photosensitizer and the long times behavior as dominated by
elimination (Figure 5).
After determining the time of accumulation and elimina-
tion of PS for both carcinoma and normal colon, one could
notice that both the accumulation and elimination time
intervals of PS were reached faster in colon carcinoma than
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in adjacent normal tissue, although the initial time of accu-
mulation (Tacc) was similar (Table 2) for both. During the
photosensitization of a tissue, there are many mechanisms
taking place, which determine the observed times. The
mechanism by which the PS is localized preferentially in can-
cerous tissue is still not well understood, but it is believed to
be associated with the tumor characteristics including an
increased number of low-density lipoprotein receptors, the
presence of macrophages, low pH, large interstitial space,
leaky vasculature, large amounts of newly synthesized col-
lagen, and high lipid content [24, 25]. Additionally, tumors
usually present a density of vessels that is higher than normal
tissue. This fact contributes to an increase in the drug
uptake rate, resulting in a faster accumulation in the tumor.
Meanwhile, the considerable high amounts of immature
collagen fibers that are present on the tumor allow the
higher accumulation quantity. The photosensitizer is also
predominantly retained in tumor stroma that is the main
component of the collagen fibers [12, 25]. For this reason,
it is believed that tumors can accumulate a higher amount of
sensitizer, as observed through the presented measurements.
The observation of almost twice more PS on the tumor than
on the normal tissue after one hour is in clear agreement with
this argument. On the other hand, the PS was eliminated
slower from normal tissue than from carcinoma tissue,
suggesting that the vascular network and the lymphatic
system surrounding the tumor are the determinant factors
of the elimination time [12, 25].
This result follows the same behavior described by
Melo et al. [6] that observed the faster accumulation of Pho-
togem in the liver (30min) and kidney (40min), while a
slower one has been observed for skin, indicating that the
clearance time between PS administration and performance
of PDT is intimately correlated with the tissue being treated.
We verify that selectivity seems to be a monotonic func-
tion of time: a decrease is always observed (Table 3 and
Figure 6). This behavior is an indication that the main
contribution to selectivity arises from the accumulation
mechanisms more than from elimination mechanisms.
The interval between photosensitizer administration and
illumination is based on the time at which there is maximal
diﬀerence between PS uptake in target tissue and surround-
ing normal tissue.
The initial interest in PDT was based on the selective
retention of PS in tumors promoting selective tumor de-
struction [26]. Haematoporphyrin derivatives accumulation
in a tissue is probably due to host factors, that is, vascular per-
meability and lymphatic clearance, coupled with its ability
to dissociate from serum protein-binding sites and bind to
cellular sites [24, 25].
In terms of measurement of PS concentration in vivo,
there is clear evidence that the variation of drug concentra-
tion among subjects, and even the variation within tumor,
can be very large [10]. Another important observation is the
fact that Photogem is not a chemically pure compound but
a mixture of purified fractions of hematoporphyrin derivate,
oligomeric and monomeric porphyrins, and when in solu-
tion it tends to dimerize, and this type of reaction may per-
haps contribute to a variance in fluorescence signal [6]. The
Photogem fluorescence intensity rapidly grew for both colon
carcinoma and normal colon reaching the maximum values
1 and 3 hours after PS injection, respectively.
Another important point to be considered in the analysis
is that tissue absorption of the excitation and fluorescence
light is diﬃcult to be avoided, since the excitation and the
very fluorescence of the PS molecules are aﬀected by the sur-
rounding medium. Even using lesion autofluorescence pre-
vious to sensitization to account for those modifications, it
would not avoid completely this eﬀect, because the PS mol-
ecule own emission is modified in tissue. So, we have used
only the fluorescence collected from the sensitized lesion, and
such consideration may have an influence on the fluctuation
observed for PS concentration on the collected data.
For Photofrin the maximal tumor selectivity ratio (2 : 1)
between tumor and normal tissue has been found between 1
and 2 hours after intravenous injection for early-stage squa-
mous cell carcinomas of the oral cavity, the upper aerodiges-
tive tract, the esophagus, and the tracheobronchial tree [15],
which is in accordance with the data from our present study
for colon carcinoma. The maximum selectivity about 2.5 : 1
was reached after 1 hour of the Photogem injection (Table 3
and Figure 6).
The photosensitizer is also predominantly retained in
tumor stroma, with no detectable diﬀerence between tumor
mucosa and normal mucosa [26]. Ideally, the photosensi-
tiser should be selectively retained within the tumor to be
destroyed withminimal retention in the surrounding normal
tissues. Such high selectivity, however, is not attained with
currently used photosensitizers (haematoporphyrin deriva-
tive and its purified versions), and therefore damage to nor-
mal tissues has to be considered, although this is acceptable
provided that safe healing occurs [26].
In order to eradicate a tumor, all malignant cells must be
destroyed, mainly those in the area where the tumor is invad-
ing normal tissue. Apparently, the photosensitizer selectivity
for tumor tissue, in this region, does not seem to oﬀer
many therapeutic benefits. The results may support evidence
that, during PDT treatments, it would be necessary to use
treatment parameters that kill at least some normal tissue to
obtain complete eradication of a tumor [12].
The results reported in the present study show that
the method of in vivo fluorescence spectroscopy showed
to be an useful technique that may be readily applied to
obtain information related to the pharmacokinetic behavior
of fluorescent drugs in dimethylhydrazine- (DMH-) induced
colonic tumors and adjacent normal colon, according to
other studies that evaluated, by the same technique, the
kinetics of HpD in organs such as kidney, liver [6], and skin
[9].
Many investigators only compare the photosensitizer
uptake in subcutaneously transplanted tumors with that in
surrounding tissues (muscle and skin), and such results have
little relevance to clinical practice for tumors of organs such
as the colon [12]. In the present study, the PS uptake was
carried out in an animalmodel of colon cancer therefore with
the similar microenvironment is found in clinical practice.
In the studied interval, the drug concentration between
tumor and normal tissue assumes a selectivity which is still
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decreasing with time. Above 4 h, it seems that selectivity
becomes independent of time. Also for the selected interval,
the drug concentration on the tumor compared to the nor-
mal tissue is always above 70% higher, which has been
considered appropriate to perform PDT.
As a final concern on the validity of the assumptions
here made, it should be emphasized that this is an initial
study. Evidence observed here is not conclusive, but allows
estimating a good interval to the use of haematoporphyrin
derivatives in rats for the treatment of colon carcinoma.
Besides, improving fluorescence techniques with biochem-
ical analyses might allow better understanding on the PS
dynamics in normal and abnormal tissue. Performing those
trials shall be the emphasis of future studies.
5. Conclusion
Pharmacokinetics monitoring has the determination of
better time windows for the performance of PDT treatment
as a main purpose. Data presented here is initial, and studies
using larger experimental groups and evaluating biochemical
information resulting form kinetics. However, this initial
study evidences a best compromise between selectivity and
drug concentration for colon carcinoma in rats and that this
takes place during the interval between 1 to 4 h after PS
injection.
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